Recognizing Drug Use in Adolescents
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
International Narcotics Control Strategy Report
United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2017 INCSR 2017 Volume 1 Table of Contents Table of Contents Common Abbreviations ............................................................................................................................. iii International Agreements .......................................................................................................................... v INTRODUCTION ........................................................................................................................................... 1 Policy and Program Developments ......................................................................................................... 17 Overview ................................................................................................................................................. 18 Methodology for U.S. Government Estimates of Illegal Drug Production ............................................... 24 (with dates ratified/acceded) ................................................................................................................... 30 USG Assistance ..................................................................................................................................... 36 International Training ............................................................................................................................. -
Fuel Properties Comparison
Alternative Fuels Data Center Fuel Properties Comparison Compressed Liquefied Low Sulfur Gasoline/E10 Biodiesel Propane (LPG) Natural Gas Natural Gas Ethanol/E100 Methanol Hydrogen Electricity Diesel (CNG) (LNG) Chemical C4 to C12 and C8 to C25 Methyl esters of C3H8 (majority) CH4 (majority), CH4 same as CNG CH3CH2OH CH3OH H2 N/A Structure [1] Ethanol ≤ to C12 to C22 fatty acids and C4H10 C2H6 and inert with inert gasses 10% (minority) gases <0.5% (a) Fuel Material Crude Oil Crude Oil Fats and oils from A by-product of Underground Underground Corn, grains, or Natural gas, coal, Natural gas, Natural gas, coal, (feedstocks) sources such as petroleum reserves and reserves and agricultural waste or woody biomass methanol, and nuclear, wind, soybeans, waste refining or renewable renewable (cellulose) electrolysis of hydro, solar, and cooking oil, animal natural gas biogas biogas water small percentages fats, and rapeseed processing of geothermal and biomass Gasoline or 1 gal = 1.00 1 gal = 1.12 B100 1 gal = 0.74 GGE 1 lb. = 0.18 GGE 1 lb. = 0.19 GGE 1 gal = 0.67 GGE 1 gal = 0.50 GGE 1 lb. = 0.45 1 kWh = 0.030 Diesel Gallon GGE GGE 1 gal = 1.05 GGE 1 gal = 0.66 DGE 1 lb. = 0.16 DGE 1 lb. = 0.17 DGE 1 gal = 0.59 DGE 1 gal = 0.45 DGE GGE GGE Equivalent 1 gal = 0.88 1 gal = 1.00 1 gal = 0.93 DGE 1 lb. = 0.40 1 kWh = 0.027 (GGE or DGE) DGE DGE B20 DGE DGE 1 gal = 1.11 GGE 1 kg = 1 GGE 1 gal = 0.99 DGE 1 kg = 0.9 DGE Energy 1 gallon of 1 gallon of 1 gallon of B100 1 gallon of 5.66 lb., or 5.37 lb. -
Preferred Drug List (PDL) OREGON HEALTH PLAN Trilliumohp.Com
Preferred Drug List (PDL) OREGON HEALTH PLAN TrilliumOHP.com 1-877-600-5472 TTY: 711 MCA_EK16V5 Approved 01/01/2019 OHP-TRIL-17-195 Pharmacy Program Trillium Community Health Plan’s goal is to offer the right drug coverage to our members. We work with doctors and pharmacists to make sure we offer drugs used to treat many conditions and illnesses. Trillium covers prescription and some over the counter drugs when they are ordered by a licensed prescriber. The pharmacy program does not cover all drugs. Some drugs need our prior approval. Some have a limit on the amount of drug that can be given. Sometimes you must get Trillium’s prior approval. Even with approval, we will not pay if you are no longer on OHP or if the treatment isn’t covered by OHP. To be paid, the treatment must follow treatment guidelines. This might include step therapy, meaning trying less costly treatment options first. Medications newly approved by the FDA (Food and Drug Administration) require prior- approval until reviewed by our Pharmacy and Therapeutics Committee. Filling a Prescription You can have your prescriptions filled at a Trillium network pharmacy. At the pharmacy, you will need to give the pharmacist your prescription and your ID card. You can find a pharmacy that is in network by calling a Trillium Member Services Representative at 541-485-2155; Toll Free: 1-877-600-5472, or by using the Find a Provider tool on our website at https://providersearch.trilliumhealthplan.com. You do not have to pay for covered drugs. The Trillium preferred drug list has a large number of brand name and generic drugs on it. -
2012-2015 Ryan White Part B Program Comprehensive Plan
2012-2015 Ryan White Part B Program Comprehensive Plan Table of Contents Acronyms ............................................................................................................................... 1 Acknowledgements ................................................................................................................ 5 Introduction ............................................................................................................................ 6 WV Comprehensive Planning Process .......................................................................... 6 Executive Summary ............................................................................................................... 7 1. Where Are We Now: What is our Current System of Care? ................................... 8 HIV/AIDS In West Virginia-Epidemiologic Trends ..................................................... 8 Unmet Need ................................................................................................................. 24 2010 Unmet Need Framework Report ......................................................................... 27 Early Identification of Individuals with HIV/AIDS (EIIHA) ...................................... 43 Prevention Programs .................................................................................................... 49 Partner Services ........................................................................................................... 50 Continuum of Care ...................................................................................................... -
Surveillance of Drug Abuse Trends in the State of Ohio January - June 2019
OSAMOSAM OhioOhio Substance Substance Abuse Abuse Monitoring Monitoring Network Network SurveillanceSurveillance of of Drug Drug Abuse Abuse Trends Trends in the State of Ohio January - June 2019 Lake Ashtabula Fulton Lucas Williams Ottawa Geauga Cuyahoga Defiance Henry Wood Sandusky Erie Lorain Trumbull Huron Summit Portage Paulding Seneca Medina Putnam Hancock Mahoning Van Wert Wyandot Crawford Ashland Wayne Stark Columbiana Allen Richland Hardin Marion Mercer Auglaize Holmes Carroll Morrow Tuscarawas Jefferson Logan Knox Shelby Union Delaware Coshocton Harrison Champaign Darke Licking Miami Guernsey Belmont Franklin Muskingum Clark Madison Montgomery Preble Fairfield Perry Noble Monroe Greene Pickaway Fayette Morgan Hocking Washington Butler Warren Clinton Ross Athens Vinton Hamilton Highland Clermont Pike Meigs Jackson Brown Adams Scioto Gallia Lawrence Legend Akron-Canton region Columbus region Athens region Dayton region Cincinnati region Toledo region Cleveland region Youngstown region Ohio Substance Abuse Monitoring Network Surveillance of Drug Abuse Trends in the State of Ohio January - June 2019 Prepared by: Ohio Department of Mental Health and Addiction Services Office of Quality, Planning and Research R. Thomas Sherba, OSAM Principal Investigator — PhD, MPH, LPCC Sarah Balser, OSAM Coordinator — MPH, MSW, LSW, CHES Jessica Linley, OSAM Quantitative Data Analyst — PhD, MSW, LSW Table of Contents OSAM-O-Gram....................................................................................................................................................................3 -
Automotive Gasoline Cas # 8006-61-9
AUTOMOTIVE GASOLINE CAS # 8006-61-9 Agency for Toxic Substances and Disease Registry ToxFAQs September 1996 This fact sheet answers the most frequently asked health questions (FAQs) about automobile gasoline. For more information, call the ATSDR Information Center at 1-888-422-8737. This fact sheet is one in a series of summaries about hazardous substances and their health effects. This information is important because this substance may harm you. The effects of exposure to any hazardous substance depend on the dose, the duration, how you are exposed, personal traits and habits, and whether other chemicals are present. SUMMARY: Exposure to automotive gasoline most likely occurs from breathing its vapor at a service station while filling a car’s fuel tank. At high levels, automotive gasoline is irritating to the lungs when breathed in and irritating to the lining of the stomach when swallowed. Exposure to high levels may also cause harmful effects to the nervous system. Automotive gasoline has been found in at least 23 of the 1,430 National Priorities List sites identified by the Environmental Protection Agency (EPA). What is automotive gasoline? � Other chemicals in gasoline dissolve in water after spills to surface waters or underground storage tank leaks into (Pronounced ô ) the groundwater. 't;-miftlv gasf;-len' The gasoline discussed in this fact sheet is automotive used � In surface releases, most chemicals in gasoline will prob as a fuel for engines in cars. Gasoline is a colorless, pale brown, or ably evaporate; others may dissolve and be carried away by water; a few will probably stick to soil. -
Cleveland Region OSAM Ohio Substance Abuse Monitoring Network
Surveillance of Drug Abuse Trends in the Cleveland Region OSAM Ohio Substance Abuse Monitoring Network Drug Abuse Trends in the Cleveland Region Regional Epidemiologist: Kathryn A. Coxe, MSW, LSW Data Sources for the Cleveland Region This regional report was based upon qualitative data collected via focus group interviews. Participants were active and recovering drug users recruited from alcohol and other drug treatment programs in Cuyahoga, Medina and Wayne counties. Data triangulation was achieved through comparison of participant data to qualitative data collected from regional community professionals (treatment providers and law enforcement) via focus group interviews, as well as to data surveyed from the Cuyahoga County Medical Examiner’s Office, the Lake County Crime Lab, the Ohio Bureau of Criminal Investigation (BCI) and the Ohio Department of Public Safety (ODPS), which logs drug task force seizures from across Ohio. All secondary data are summary data of cases processed from July through OSAM Staff: December 2017. In addition to these data sources, Ohio media outlets were queried for information regarding R. Thomas Sherba, PhD, MPH, LPCC regional drug abuse for January through June 2018. OSAM Principal Investigator Note: OSAM participants were asked to report on drug use/ Kathryn A. Coxe, MSW, LSW knowledge pertaining to the past six months prior to the interview; OSAM Coordinator thus, current secondary data correspond to the reporting period of participants. Jessica Linley, PhD, MSW, LSW OSAM Quantitative Data Analyst OSAMOSAM -
Safe Handling and Disposal of Chemicals Used in the Illicit Manufacture of Drugs
Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Safe handling and disposal of chemicals used in the illicit manufacture of drugs United Nations publication USD 26 Printed in Austria ISBN 978-92-1-148266-9 Sales No. E.11.XI.14 ST/NAR/36/Rev.1 V.11-83777—September*1183777* 2011—300 Guidelines for the Safe handling and disposal of chemicals used in the illlicit manufacture of drugs UNITED NATIONS New York, 2011 Symbols of United Nations documents are composed of letters combined with figures. Mention of such symbols indicates a reference to a United Nations document. ST/NAR/36/Rev.1 UNITED NATIONS PUBLICATION Sales No. E.11.XI.14 ISBN 978-92-1-148266-9 eISBN 978-92-1-055160-1 © United Nations, September 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Requests for permission to reproduce this work are welcomed and should be sent to the Secretary of the Publications Board, United Nations Headquarters, New York, N.Y. 10017, U.S.A. or also see the website of the Board: https://unp.un.org/Rights.aspx. Governments and their institutions may reproduce this work without prior authoriza- tion but are requested to mention the source and inform the United Nations of such reproduction. -
Estimates of Nitrous Oxide Emissions from Motor Vehicles and the Effects of Catalyst Composition and Aging
ESTIMATES OF NITROUS OXIDE EMISSIONS FROM MOTOR VEHICLES AND THE EFFECTS OF CATALYST COMPOSITION AND AGING Contract No. 02-313 STATE OF CALIFORNIA AIR RESOURCES BOARD Final Report Prepared by Arthur M. Winer, Ph.D. Principal Investigator Environmental Health Sciences Department and Environmental Science and Engineering Program School of Public Health University of California, Los Angeles, California, 90095 (310) 206-1278 Eduardo Behrentz, D.Env. Co-Investigator Environmental Science and Engineering Program School of Public Health University of California, Los Angeles June 10, 2005 N2O Emissions from Motor Vehicles DISCLAIMER The statements and conclusions in this report are those of the contractor and not necessarily those of the California Air Resources Board. The mention of commercial products, their source, or their use in connection with material reported herein is not to be constructed as actual or implied endorsement of such products. i N2O Emissions from Motor Vehicles ii N2O Emissions from Motor Vehicles ACKNOWLEDGEMENTS The contributions of the California Air Resources Board staff, particularly Paul Rieger, who made invaluable suggestions and contributions throughout the project, and Hector Maldonado who acted as our Project Officer, were greatly appreciated. We also thank Richard Ling of the Monitoring and Laboratory Division who collected all emissions data from the 16th Vehicle Surveillance Program and who provided on-site training and support. We thank Margo Eaddy for her participation during the data collection process. We wish to acknowledge valuable contributions from Jerry Ho and Robin Lang of the Mobile Source Operations Division who provided logistical support during vehicle testing and data collection. We especially appreciated Shane Michael, the project’s Test Engineer, of the Mobile Source Operations Division for his professionalism and willingness to assist us throughout the study. -
Synthetic Cannabinoid Induced Psychosis in a Previously Nonpsychotic Patient
The American Journal on Addictions, 21: 287–288, 2012 Copyright C American Academy of Addiction Psychiatry ISSN: 1055-0496 print / 1521-0391 online DOI: 10.1111/j.1521-0391.2012.00222.x Synthetic Cannabinoid Induced Psychosis in a Previously Nonpsychotic Patient Stephanie Peglow, DO,1 Jessica Buchner, BS, MS III,1 Gregory Briscoe, MD2 1Department of Psychiatry and Behavioral Medicine, Eastern Virginia Medical School, Norfolk, Virginia 2Department of Psychiatry, Hampton Veterans Affairs Medical Center, Hampton, Virginia Synthetic cannabinoids are relatively new substances cannabis,6,7 conventional merchant availability, and poten- that have become rapidly popular among young adults. tially negative health impact, synthetic cannabinoids are Despite their legal status in most states, they are virtually anticipated to be an emerging issue in the field of substance unregulated and unstudied. Nevertheless, recent case stud- abuse. ies have brought new attention to their potentially harmful side effects, such as psychosis, agitation, and withdrawal. This case report examines the acute psychosis displayed CASE REPORT by a psychiatric patient after smoking “Spice,” a substance comprised of various synthetic cannabinoids, on three sep- Mr. G is a 59-year-old Latino male with a history of arate occasions. Furthermore, in comparing this patient’s post-traumatic stress disorder (PTSD) and polysubstance lack of psychotic symptoms after tetrahydrocannabinol abuse. Without a prior history of psychosis, he was admit- (THC) use, to the episodes of psychosis experienced af- ted to the same inpatient psychiatric unit three times over a ter “Spice” consumption this case study explores the pos- period of 60 days for the development of psychotic symp- sibility that synthetic cannabinoids are more potent than toms after smoking “Spice.” The patient has a long history their organic counterpart. -
Drug Abuse Treatment
If you have issues viewing or accessing this file contact us at NCJRS.gov. '., S1 ATISTICAl PERSPECTIVES ON DRUG ABUSE TREATMENT ~N NEW JERSEYg 1986 New Jersey Department @f Health Ai«:@ho~, Narcotic Olnd Drug Abuse OHke of [i)(OJta All1alysis and Epidemiology CN362 Trenllf@n, INlJl 08625-0362 114982 U.S. Department of Justice National Institute of Justice This document has been reproduced exactly as received from the person or organization originating it. Points of view or opinions stated in this document are those of the authors and do not necessarily represent the official position or policies of the National Institute of Justice. Permission to reproduce this copyrighted material has been gr.,;mted by :.'leW LTersey State Department -'6fKeaI'Eh ... -.. ------------,------ to the National Criminal Justice Reference Service (NCJRS). Fiirlher roproduction outside of the NCJRS system requiros permis sion of the copyright ownor. PREFACE This is the fourth annual report on clients of New Jersey's drug abuse treatment system. It, as did its predecessors, attempts a statistical description of drug abusers in treatment; who they are demographically, what they use, what treatment they get, how long they stay in treatment, and whether or not they succeed in completing their treatment plans. Before we go on to developing answers to these questions, perhaps we should pause to consider why we should be concerned, why drug abusers affect us. I believe the answer to this question is because drug abuse affects all of us. Families and friends of drug abusers worry over the self-destructive acts of abusers--their loss of employment, trouble with the police, "hanging out" with undesirable associates, and now over the possibility that they may get AIDS through sharing needles. -
Volatile Solvents As Drugs of Abuse: Focus on the Cortico-Mesolimbic Circuitry
Neuropsychopharmacology (2013) 38, 2555–2567 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Review Volatile Solvents as Drugs of Abuse: Focus on the Cortico-Mesolimbic Circuitry 1,2 ,1,2 Jacob T Beckley and John J Woodward* 1 2 Department of Neurosciences, Medical University of South Carolina, Charleston, SC, USA; Center for Drug and Alcohol Programs, Department of Psychiatry/Neurosciences, Medical University of South Carolina, Charleston, SC, USA Volatile solvents such as those found in fuels, paints, and thinners are found throughout the world and are used in a variety of industrial applications. However, these compounds are also often intentionally inhaled at high concentrations to produce intoxication. While solvent use has been recognized as a potential drug problem for many years, research on the sites and mechanisms of action of these compounds lags behind that of other drugs of abuse. In this review, we first discuss the epidemiology of voluntary solvent use throughout the world and then consider what is known about their basic pharmacology and how this may explain their use as drugs of abuse. We next present data from preclinical and clinical studies indicating that these substances induce common addiction sequelae such as dependence, withdrawal, and cognitive impairments. We describe how toluene, the most commonly studied psychoactive volatile solvent, alters synaptic transmission in key brain circuits such as the mesolimbic dopamine system and medial prefrontal cortex (mPFC) that are thought to underlie addiction pathology. Finally, we make the case that activity in mPFC circuits is a critical regulator of the mesolimbic dopamine system’s ability to respond to volatile solvents like toluene.